Compare HTZ & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | AGMB |
|---|---|---|
| Founded | 1918 | 2017 |
| Country | United States | Belgium |
| Employees | 26000 | 62 |
| Industry | Rental/Leasing Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 669.4M | 562.4M |
| IPO Year | N/A | N/A |
| Metric | HTZ | AGMB |
|---|---|---|
| Price | $1.81 | $12.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.67 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 26.8M | 89.8K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $3.62 | $17.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.71 | $8.75 |
| 52 Week High | $8.18 | $17.82 |
| Indicator | HTZ | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 24.98 | 51.94 |
| Support Level | N/A | $9.54 |
| Resistance Level | $5.42 | $14.19 |
| Average True Range (ATR) | 0.16 | 1.01 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 20.93 | 49.91 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.